Vellux 100UI
Next-generation neuromodulator with 3D effect technology | 98.7% pure neurotoxin complex
Advanced 3D Effect Technology & Protein-Free Formula
Vellux™ utilizes AEGEN Bio’s patented purification process (KR Patent No. 10-2018-0098765) to produce the most concentrated botulinum toxin type A formulation available. With zero animal-derived proteins, 98.7% pure neurotoxin complex, and 300kDa molecular weight, it demonstrates 42% lower diffusion radius compared to conventional neuromodulators. Clinical studies show visible effects from day 3 post-injection with duration extending to 8 months in 78% of cases (n=450 multicenter trial).
Clinically Demonstrated Advantages
Rapid Onset
Visible effects from day 3 (vs industry average 5-7 days) with full effect by day 14
Extended Duration
6-8 month efficacy in 78% of patients (vs 3-4 months for conventional toxins)
Precision Diffusion
42% smaller diffusion radius enables precise anatomical targeting
Enhanced Safety
Protein-free formula reduces antibody formation risk by 87%
Pharmaceutical Specifications
- Active Substance: Botulinum Toxin Type A 100U/vial
- Presentation: Lyophilized powder in colorless vial
- Purity: 98.7% neurotoxin complex
- Excipients: Sucrose, NaCl (protein-free)
- Storage: 2-8°C protected from light
- Shelf Life: 24 months unopened
Clinical Protocol
- Reconstitution: Use preservative-free saline (recommended 2.5ml/vial)
- Dosage: 4-20U per treatment area (physician discretion)
- Needle: 30-32G ultra-fine for precision delivery
- Administration: Intramuscular or intradermal injection
- Frequency: Every 6-8 months based on patient response
Therapeutic Applications
Cosmetic Indications
Glabellar lines: 10-20U total dose divided across 5 injection points. Maxillary folds: 8-12U per side. Clinical studies show 92% patient satisfaction at 4-week follow-up.
Hyperhidrosis
Axillary: 50U per axilla via 10-15 intradermal injections. Palmar: 60-80U per palm. Achieves 89% sweat reduction lasting 7.3 months average.
Scar Prevention
Post-surgical: 5-10U along incision lines within 48 hours of closure. Reduces hypertrophic scarring by 73% versus controls.
Important Clinical Notice
Notice: Individual results may vary significantly based on anatomical factors, injection technique, and biological response. Vellux™ must only be administered by board-certified physicians trained in neuromodulator techniques. Absolute contraindications include: neuromuscular disorders (myasthenia gravis, ALS), pregnancy/lactation, and hypersensitivity to any component.
This product is not FDA-approved. All cosmetic uses are off-label. Monitor patients for 15 minutes post-injection for potential adverse reactions including ptosis, dysphagia, or generalized weakness. AEGEN Bio assumes no liability for improper use or unlicensed administration.
